Bristol-Myers Squibb Co. (BMY) Company Profile & Statistics

Bristol-Myers Squibb Co.
BMY
(NYSE)
Closed
58.23
+0.35 (+0.60%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
58.16
High
58.47
Low
57.49

About Bristol-Myers Squibb Co.

CEO

Christopher Boerner

Headquarters

route 206 and province line road

princeton, nj 08543, united states

Auditor

DELOITTE & TOUCHE LLP

Employees

34,100

Share Holders

31,207

Website

www.bms.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.

Bristol-Myers Squibb Co. Statistics

Valuation Measures

Market Capitalization ²	118.10B
Enterprise Value	159.96B
Enterprise Value/EBITDA (ttm)	48.41
Price to Earnings Ratio (ttm)	49.77
Price to Book (mrq)	6.87
Price to Sales (ttm)	2.49
Price to Cash (ytd)	4.67

Profitability

Gross Margin (ttm)	74.93%
Operating Margin (ttm)	5.05%
Profit Margin (ttm)	-15.27%
Return on Equity (ttm)	11.94%
Return on Invested Capital (ttm)	-10.97%
Return on Assets (ttm)	2.51%

Income Statement

Revenue (ttm)	47.44B
Revenue Per Share (ttm)	23.39
Gross Profit (ttm)	35.53B
EBITDA (ttm)³	3.30B
Net Income Avi to Common (ttm)	-7.26B
Diluted EPS (ttm)	-3.59

Share Statistics

Beta (5Y Monthly)	0.44
52-Week Change	25.10%
S&P500 52-Week Change	31.08%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	2.03B
Dividend Yield	4.12%
Float ⁴	2.03B
% Held by Insiders	0.09%
% Held by Institutions	76.41%

Balance Sheet

Total Cash (mrq)	8.09B
Total Cash Per Share (mrq)	3.99
Total Debt (mrq)	49.75B
Total Debt/Equity (mrq)	289.26%
Current Ratio (mrq)	1.24%
Quick Ratio (mrq)	1.09%
Book Value Per Share (mrq)	8.48

Cash Flow

Operating Cash Flow Per Share (ytd)	5.29
Free Cash Flow (ytd)	9.88B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Bristol-Myers Squibb Co.

Trade With A Regulated Broker